Article info
PDFDrug therapy
Short report
Biosimilar infliximab use in paediatric IBD
- Correspondence to Lisa Richmond, Paediatric Clinical Research Facility, Neurosciences building, Queen Elizabeth University Hospital, Glasgow G51 4TF, UK; lisa.richmond{at}nhs.net
Citation
Biosimilar infliximab use in paediatric IBD
Publication history
- Received May 16, 2017
- Revised August 26, 2017
- Accepted September 6, 2017
- First published October 7, 2017.
Online issue publication
December 13, 2017
Article Versions
- Previous version (7 October 2017).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/